PCSK9 and homozygous familial hypercholesterolemia: For most HoFH patients, the current lipid-lowering therapies, such as plasmapheresis, LDL apheresis, or liver transplantation, and cholesterol-lowering drugs (e.g., high-dose statins) are not able to reduce LDL-C to normal levels and also have adverse side effects.4, 5, 6 In recent years, PCSK9 inhibitors, such as evolocumab and alirocumab, have emerged as the newer generation of lipid-lowering drugs and can significantly reduce LDL-C in HeFH and non-familial hypercholesterolemia (non-FH) patients.7